Paying Cancer in Its Own Coin: One of Clay B. Siegall’s Most Powerful Propelling Force

More often than not, great achievers are propelled to great heights by a greater force than mean accomplishers. I have studied a couple of successive people in business and other human endeavors and discovered the above postulation is true. My last case of study was Clay B. Siegall; the outcome is nothing different, and I am not surprise he is doing amazing things in his chosen profession. He has a driving force that is sure to keep him going all the way.

Clay B. Siegall revealed in a recent interview that he got bitter with the monster called cancer while he was only 19 years old seeing his beloved father battling with the disease. By the time he turned 24, the father died of the same ailment. It was after this horrible experience that he decided to pursue a Ph.D. in Genetics at George Washington University with specialization on targeted cancer therapies. You do not need a prophet to tell you why he chose that line of career. Obviously, he was out to pay cancer in its own coin. Good enough, he has been able to achieve this goal and still keep dealing devastating blows on the monster.

One good thing I love about this noble personality is that he does not claim to know everything. In fact, he believes he knows far too little, so he collaborates with other great minds in the war against cancer. Even the company he co-founded, Seattle Genetics, imbibes this approach to business which has helped the company scale unimaginable heights. For instance, Seattle Genetics has turned out fantastic antibody-drug conjugates (ADCs) over the years. The FDA approved its first ADC product, ADCETRIS® (brentuximab vedotin) in 2011. Today, the drug has become a global brand, approved and used by well over 65 countries through the collaboration of Seattle Genetics with Takeda Pharmaceutical Company. This is just one of the numerous collaborations the company is involved in.

With no iota of doubt, Clay B. Siegall is a priceless asset in the war against cancer. He has a mind-boggling 15 patents to his credit. That is phenomenal by all standards. Little wonder, he has an avalanche of awards from many international bodies including the 2012 Pacific Northwest Ernst & Young Entrepreneur of the Year Award as well as the 2013 University of Maryland Alumnus of the Year for Computer, Math and Natural Sciences Award.